FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006904920> ?p ?o ?g. }

• W2006904920 endingPage "594" @default.
• W2006904920 startingPage "588" @default.
• W2006904920 abstract "In 1982, the Illinois Cancer Center initiated a Phase II trial in which the following treatment was administered: Induction chemotherapy (cisplatin and infusional 5-fluorouracil [5-FU]) was administered before definitive local therapy. Definitive local therapy, consisting of surgery, radiation, or both, was followed by three cycles of the same chemotherapy program.Eligible patients had Stage III or IV squamous cell carcinoma of the head and neck with no distant metastases. Three cycles of induction chemotherapy were given. Cisplatin, 100 mg/m2, was infused over 60 minutes on Day 1; thereafter, 5-FU (1000 mg/m2/day) was given continuously for 5 days. Cycles were repeated at 3-week intervals. Local therapy was individualized, according to tumor stage and site. Patients who responded were to receive an additional three cycles of chemotherapy after surgery or radiation.Eighty-one patients were entered into the trial, and 71 were considered both eligible and evaluable. After induction chemotherapy, 59 patients (83%) responded, 23 of whom experienced complete response. Sixty-nine patients completed definitive local treatment, but only 22 proceeded to the planned adjuvant cycles of treatment. Median follow-up of surviving patients was 12 years. At last follow-up, 13 patients were alive and free of malignancy, 9 of whom never had disease recurrence or a second primary tumor. These 13 patients had an acceptable quality of life, were ambulating, and were fully capable of caring for themselves. Overall, nine patients had second primary malignancies. Thirty-four percent of patients were alive at 5 years, and 21% were alive at 10 years. Of 58 deaths, 44 resulted from progressive disease and 8 resulted from second primary cancers. Four patients died of unrelated causes, and two suffered lethal acute toxicity from the chemotherapy program. Late toxicity was moderate. Among 23 patients surviving at least 6 years, there were 3 cases of hypothyroidism, presumed to be secondary to radiation. Xerostomia was modest, consistent with usual radiation effects. Of the 13 patients who were alive and free of malignancy at last follow-up, none had clinical manifestations of serious late end organ toxicity.During long term follow-up after multimodal treatment of locally advanced squamous cell carcinoma, no obvious benefit was observed from the chemotherapy component of the treatment regimens rendered. Only 21% of patients achieved 10-year survival with the following causes of failure, in descending order of frequency: disease recurrence, second malignancies, other medical problems, and treatment-related deaths. The results of this trial are consistent with the results of other induction chemotherapy trials, indicating the need for innovative treatment strategies. These data do not support the continued use of induction chemotherapy with the cisplatin and infusional 5-FU program." @default.
• W2006904920 created "2016-06-24" @default.
• W2006904920 creator A5000384489 @default.
• W2006904920 creator A5017187936 @default.
• W2006904920 creator A5042995920 @default.
• W2006904920 creator A5043943818 @default.
• W2006904920 creator A5056297454 @default.
• W2006904920 creator A5059298173 @default.
• W2006904920 creator A5063904421 @default.
• W2006904920 creator A5067854784 @default.
• W2006904920 creator A5080379447 @default.
• W2006904920 creator A5083824775 @default.
• W2006904920 date "1997-02-01" @default.
• W2006904920 modified "2023-09-24" @default.
• W2006904920 title "Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck" @default.
• W2006904920 cites W1901801026 @default.
• W2006904920 cites W1986884101 @default.
• W2006904920 cites W2010410598 @default.
• W2006904920 cites W2041892737 @default.
• W2006904920 cites W2090293084 @default.
• W2006904920 cites W2096156091 @default.
• W2006904920 cites W2151616125 @default.
• W2006904920 cites W2210366913 @default.
• W2006904920 cites W2258719021 @default.
• W2006904920 cites W2280243609 @default.
• W2006904920 cites W2406213538 @default.
• W2006904920 cites W2562414697 @default.
• W2006904920 cites W4246987999 @default.
• W2006904920 doi "https://doi.org/10.1002/(sici)1097-0142(19970201)79:3<588::aid-cncr23>3.0.co;2-z" @default.
• W2006904920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9028372" @default.
• W2006904920 hasPublicationYear "1997" @default.
• W2006904920 type Work @default.
• W2006904920 sameAs 2006904920 @default.
• W2006904920 citedByCount "23" @default.
• W2006904920 countsByYear W20069049202015 @default.
• W2006904920 crossrefType "journal-article" @default.
• W2006904920 hasAuthorship W2006904920A5000384489 @default.
• W2006904920 hasAuthorship W2006904920A5017187936 @default.
• W2006904920 hasAuthorship W2006904920A5042995920 @default.
• W2006904920 hasAuthorship W2006904920A5043943818 @default.
• W2006904920 hasAuthorship W2006904920A5056297454 @default.
• W2006904920 hasAuthorship W2006904920A5059298173 @default.
• W2006904920 hasAuthorship W2006904920A5063904421 @default.
• W2006904920 hasAuthorship W2006904920A5067854784 @default.
• W2006904920 hasAuthorship W2006904920A5080379447 @default.
• W2006904920 hasAuthorship W2006904920A5083824775 @default.
• W2006904920 hasConcept C121608353 @default.
• W2006904920 hasConcept C126322002 @default.
• W2006904920 hasConcept C141071460 @default.
• W2006904920 hasConcept C146357865 @default.
• W2006904920 hasConcept C151730666 @default.
• W2006904920 hasConcept C2776530083 @default.
• W2006904920 hasConcept C2776611710 @default.
• W2006904920 hasConcept C2776694085 @default.
• W2006904920 hasConcept C2778239845 @default.
• W2006904920 hasConcept C2779013556 @default.
• W2006904920 hasConcept C2779399171 @default.
• W2006904920 hasConcept C2780283643 @default.
• W2006904920 hasConcept C2780456651 @default.
• W2006904920 hasConcept C509974204 @default.
• W2006904920 hasConcept C71924100 @default.
• W2006904920 hasConcept C86803240 @default.
• W2006904920 hasConceptScore W2006904920C121608353 @default.
• W2006904920 hasConceptScore W2006904920C126322002 @default.
• W2006904920 hasConceptScore W2006904920C141071460 @default.
• W2006904920 hasConceptScore W2006904920C146357865 @default.
• W2006904920 hasConceptScore W2006904920C151730666 @default.
• W2006904920 hasConceptScore W2006904920C2776530083 @default.
• W2006904920 hasConceptScore W2006904920C2776611710 @default.
• W2006904920 hasConceptScore W2006904920C2776694085 @default.
• W2006904920 hasConceptScore W2006904920C2778239845 @default.
• W2006904920 hasConceptScore W2006904920C2779013556 @default.
• W2006904920 hasConceptScore W2006904920C2779399171 @default.
• W2006904920 hasConceptScore W2006904920C2780283643 @default.
• W2006904920 hasConceptScore W2006904920C2780456651 @default.
• W2006904920 hasConceptScore W2006904920C509974204 @default.
• W2006904920 hasConceptScore W2006904920C71924100 @default.
• W2006904920 hasConceptScore W2006904920C86803240 @default.
• W2006904920 hasIssue "3" @default.
• W2006904920 hasLocation W20069049201 @default.
• W2006904920 hasLocation W20069049202 @default.
• W2006904920 hasOpenAccess W2006904920 @default.
• W2006904920 hasPrimaryLocation W20069049201 @default.
• W2006904920 hasRelatedWork W2046102541 @default.
• W2006904920 hasRelatedWork W2089609493 @default.
• W2006904920 hasRelatedWork W2376593068 @default.
• W2006904920 hasRelatedWork W2406263212 @default.
• W2006904920 hasRelatedWork W2408953484 @default.
• W2006904920 hasRelatedWork W2409439767 @default.
• W2006904920 hasRelatedWork W2460868461 @default.
• W2006904920 hasRelatedWork W4213111474 @default.
• W2006904920 hasRelatedWork W4319705850 @default.
• W2006904920 hasRelatedWork W933517682 @default.
• W2006904920 hasVolume "79" @default.
• W2006904920 isParatext "false" @default.
• W2006904920 isRetracted "false" @default.
• W2006904920 magId "2006904920" @default.
• W2006904920 workType "article" @default.